Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China.
J Viral Hepat
October 2024
Institute of Viruses and Infectious Diseases, Nanjing University, Jiangsu, China.
Article Synopsis
- Hepatitis C virus (HCV) is a significant public health issue in China, impacting over 10 million people, prompting the HEAL program, which aimed to improve HCV surveillance and linkage to care in tertiary hospitals.
- The intervention included education for non-infectious disease physicians and a patient-navigator system to streamline testing and treatment for patients who tested positive for HCV.
- Following the HEAL program implementation, screening rates and follow-up for HCV increased significantly, leading to a higher number of confirmed active infections and improved patient linkage to care.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease.
J Pharm Bioallied Sci
July 2024
Department of Medicine, Division of Gastroenterology and Hepatology, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy.
View Article and Find Full Text PDFObjectives: Interferon (IFN)-induced lung injury is a rare but severe complication. Studies are needed to elucidate the demographic characteristics, clinical manifestations, and prognostic features of IFN-induced interstitial lung disease (ILD).
Case Report: We report a patient with chronic hepatitis who developed ILD after interferon monotherapy.
Generalized cost-effectiveness analysis to assess treatment value in hepatitis C.
Am J Manag Care
December 2023
PRECISIONheor, 2 Bethesda Metro Center, Ste 850, Bethesda, MD 20814. Email:
Objectives: To estimate the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) compared with peginterferon alfa and ribavirin (PEG/riba) employing a generalized cost-effectiveness analysis (GCEA).
Study Design: To assess the societal-level cost-effectiveness of DAA treatment for HCV, we extended a previously published discrete-time Markov simulation model of HCV transmission and progression to include market dynamics and broader elements of value.
Methods: We followed a stepwise process to add novel value elements to a traditional CEA model for HCV treatments.
Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
Medicine (Baltimore)
October 2023
Department of Digestive, China-Japan Union Hospital Affiliated to Jilin University, Changchun, China.
To investigate associations between inosine triphosphatase (ITPA) gene polymorphisms and long-term outcomes among chronic hepatitis C (CHC) patients in Northeast China treated with Peg-interferon (IFN)/ribavirin (RBV). CHC patients who received Peg-IFN-2a/RBV treatment during between 2011 and 2013 at 5 hepatitis centers in Northeast China were enrolled. ITPA single nucleotide polymorphisms rs1127354 and rs7270101 from all patients were detected and their associations with 5-year outcomes were analyzed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!